CONTRAFECT Corp
CFRXDelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001478069
CONTRAFECT Corp was delisted in 2023; its insiders filed their last Form 4 on Feb 16, 2023; 40 institutions reported holding it in 13F filings for Q4 2022, worth $1.08M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by CONTRAFECT Corp insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for CONTRAFECT Corp, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Messinger Michael | Chief Financial Officer | – | Feb 16, 2023 | 0 |
| Barer Sol J | Director | – | May 18, 2022 | 0 |
| Otto Michael J. | Director | – | May 18, 2022 | 0 |
| Gilman Steven C | Director | – | May 18, 2022 | 0 |
| Sucoff Cary | Director | – | May 18, 2022 | 0 |
| Low David N. | Director | – | May 18, 2022 | 0 |
| Aklog Lishan | Director | – | May 18, 2022 | 0 |
| Barlow Jane F | Director | – | May 18, 2022 | 0 |
| Pomerantz Roger | Chief Executive Officer | – | Feb 17, 2022 | 0 |
| Bogdanos Natalie | General Counsel | – | Feb 17, 2022 | 0 |
| Cassino Cara M | Chief Medical Officer | – | Feb 17, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
No insider trades match these filters.